Real-world signs and symptoms at diagnosis in patients with IgA nephropathy

Dario Roccatello, Julia Kattlun, Raymond Przybysz, Aneesh Thomas George, Carolina Aldworth, Clare Proudfoot, Weijia Wang, Jonathan de Courcy, Richard Lafayette

• Abstract
• Oral presentation

Population-based identification of biopsy-proven IgA nephropathy using natural language processing: The KNIGHT study

Rishi V. Parikh, Thida C. Tan, Ajit Mahapatra, Weijia Wang, Robert Perkins, Alan S. Go

• Abstract
• Oral presentation

APPLAUSE-IgAN: A multi-center, randomized, double-blind, placebo-controlled, parallel group, Phase 3 study to evaluate the efficacy and safety of LNP023 in primary IgA nephropathy patients

Vlado Perkovic, Brad Rovin, Hong Zhang, Naoki Kashihara, Bart Maes, Dana V Rizk, Wenyan Wang, Meier, Matthias, Kollins, Dmitrij, Olympia Papachristofi, Alan Charney, Jonathan Barratt

• Abstract
• Oral presentation

Final 12-week endpoint analyses of a Phase 2 dose-ranging study to investigate the efficacy and safety of iptacopan in primary IgA nephropathy

Jonathan Barratt, Brad Rovin, Hong Zhang, Naoki Kashihara, Bart Maes, Dana V Rizk, Hernan Trimarchi, Matthias Meier, Alan Charney, Wenyan Wang, Olympia Papachristofi, Vlado Perkovic

• Abstract
• Oral presentation

Iptacopan (LNP023): A novel oral complement alternative pathway factor B inhibitor safely and effectively stabilises eGFR in C3 glomerulopathy

Edwin Wong, Manuel Praga, Carla Nester, Moglie Le Quintrec, Erica Daina, Giuseppe Remuzzi, Angelo Trapani, Yaqin Wang, Liu Junhao, Guido Junge, Matthias Meier, Nicholas Webb

• Abstract
• Oral presentation

Relationship between UPCR and eGFR in C3 glomerulopathy

Carla Nester, Patrick Breheny, Monica Hall, Alan Charney, Martin Lefkowitz, Angelo Trapani, Yaqin Wang, Richard Smith

• Abstract

LNP023: A novel oral complement alternative pathway factor B inhibitor for the treatment of glomerular disease

Nicholas Webb, Börje Haraldsson, Anna Schubart, Julie Milojevic, Peter End, Thomas Holbro, Guido Junge

• Abstract
• Oral presentation

Systematic Review on Cost and Healthcare Resource Utilization in Immunoglobulin A Nephropathy (IgAN)

Doherty J, George A, Akkapantula S, Kolli NR, Pannagl K

• Abstract
• Oral presentation

Systematic Review on Health-Related Quality of Life and Utilities in Immunoglobulin A Nephropathy (IgAN)

Doherty J, George A, Akkapantula S, Kolli NR, Pannagl K

• Abstract
• Oral presentation

Systematic identification and mapping of global real-world data sources for atypical hemolytic uremic syndrome (aHUS)

Sreenu Lavudiya, Rumjhum Agrawal, Gisela Tomas Rovira, Raymond Przybysz, Rachel Studer

• Abstract
• Poster presentation

Mining SocialMedia to understand unmet need and treatment experience in patients with atypical hemolytic uremic syndrome (aHUS)

Maurya A, Dixit G, George A, Karki RG, Aasaithambi S, Verma H, Doherty JP

• Abstract
• Poster presentation

Identification and description of global real-world data (RWD) sources for IgA nephropathy (IgAN), membranous nephropathy (MN) and C3 glomerulopathy (C3G)

Tanvi Rajput, Rumjhum Agrawal, Gisela Tomas Rovira, Emil Loefroth, Rachel Studer

• Abstract
• Oral presentation

Patient insights for immunoglobulin A nephropathy (IgAN) using social media listening

Nishith Tyagi, Sathyaraj Aasaithambi, Jyoti Chauhan, Aneesh Thomas George, Nancy Zaour

• Abstract
• Poster presentation

Patient insights for complement 3 glomerulopathy (C3G) using social media listening

Nishith Tyagi, Sathyaraj Aasaithambi, Jyoti Chauhan, Aneesh Thomas George, Nancy Zaour

• Abstract
• Poster presentation

The burden associated with complement 3 glomerulopathy (C3G)

George AT, Zaour N, Nic Lochlainn E

• Abstract
• Poster presentation

The burden associated with immunoglobulin A nephropathy (IgAN)

George AT, Zaour N, Nic Lochlainn E

• Abstract
• Poster presentation

The patient journey for immunoglobulin A nephropathy: Diagnostic delay and change in kidney function from first clinical sign

Robert Perkins, Elyse Swallow, Weijia Wang, Emily Gao, Steve Olson, Jennifer Sung, Ha Nguyen, Danielle Peterson, Emma Billmyer, Alexander Chang

• Abstract
• Poster presentation

Alternative complement pathway inhibition with iptacopan to arrest disease progression in C3 glomerulopathy (APPEAR-C3G): A Phase 3 study

Richard JH Smith, David G Kavanagh, Ronda Tawfik, Angelo J Trapani, Yaqin Wang, Nicholas Webb, Matthias Meier, Marina Vivarelli, Andrew S Bomback

• Abstract
• Poster presentation

A Phase 3 study to support iptacopan registration in atypical hemolytic uremic syndrome (aHUS): Overview of APPELHUS study design considerations

David Kavanagh, Larry A. Greenbaum, Arvind Bagga, Chien-Wei-Chen, Rajeshri G. Karki, Sajita Vasudevan, Marion Dahlke, Fadi Fakhouri

• Abstract
• Poster presentation

Development of a coated mini-tablet formulation for iptacopan & evaluating the acceptability, swallowability and palatability of multiple mini-tablets in young children

Isabelle Sessler, Nicholas Webb, Philipp Lustenberger, Rama Sivasubramanian, Giulio Loforese, Juliane Münch, Hansmartin Bosse, Viviane Klingmann

• Abstract
• Poster presentation

A novel approach to assess the demographic and clinical characteristics of immunoglobulin A nephropathy (IgAN) patients in a US real-world setting

Raymond Przybysz, Rina Mehta, Gisela Rovira Tomas, Carolina Aldworth, Jim Doherty, Rachel Studer

• Poster presentation

APPLAUSE-IgAN: A multi-center, randomized, double-blind, placebo-controlled, parallel group, Phase 3 study to evaluate the efficacy and safety of LNP023 in primary IgA nephropathy patients

Vlado Perkovic, Brad Rovin, Hong Zhang, Naoki Kashihara, Bart Maes, Dana V Rizk, Wenyan Wang, Matthias Meier, Dmitrij Kollins, Olympia Papachristofi, Alan Charney, Jonathan Barratt

• Poster presentation

Also presented at ERA-EDTA 2021

Interim analysis of a Phase 2 dose-ranging study to investigate the efficacy and safety of iptacopan in primary IgA nephropathy

Jonathan Barratt, Brad Rovin, Hong Zhang, Naoki Kashihara, Bart Maes, Dana V Rizk, Hernan Trimarchi, Matthias Meier, Alan Charney, Wenyan Wang, Olympia Papachristofi, Vlado Perkovic

• Poster presentation

APPLAUSE-IgAN: A multi-center, randomized, double-blind, placebo-controlled, parallel group, Phase 3 study to evaluate the efficacy and safety of LNP023 in primary IgA nephropathy patients

Vlado Perkovic, Brad Rovin, Hong Zhang, Naoki Kashihara, Bart Maes, Dana V Rizk, Wenyan Wang, Meier Matthias, Kollins Dmitrij, Olympia Papachristofi, Alan Charney, Jonathan Barratt

• Abstract

Also presented at ERA-EDTA and DGfN 2021

Interim analysis of a Phase 2 dose-ranging study to investigate the efficacy and safety of iptacopan in primary IgA nephropathy

Jonathan Barratt, Brad Rovin, Hong Zhang, Naoki Kashihara, Bart Maes, Dana V Rizk, Hernan Trimarchi, Matthias Meier, Alan Charney, Wenyan Wang, Olympia Papachristofi, Vlado Perkovic

• Abstract

Also presented at DGfN 2021

Efficacy and safety of iptacopan in IgA nephropathy: Results of a randomized double-blind, placebo-controlled, Phase 2 study at 6 months

Jonathan Barratt, Brad Rovin, Hong Zhang, Naoki Kashihara, Bart Maes, Dana V. Rizk, Hernan Trimarchi, Ben Sprangers, Matthias Meier, Dmitrij Kollins, Wenyan Wang, Annabel Magirr, Vlado Perkovic

• Abstract
• Oral presentation
• Poster presentation

Corticosteroid use, infection, and adverse events among immunoglobulin A nephropathy (IgAN) patients in a US real-world setting

Carolina Aldworth, Robert Perkins, Julia Kattlun, Jim Doherty, Aneesh Thomas George, Jaydeep Das, Weijia Wang, Raymond Przybysz

• Abstract
• Poster presentation